Related Experiment Video

Updated: Apr 12, 2026

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

9.0K

Effect of STAT3 inhibition on the metabolic switch in a highly STAT3-activated lymphoma cell line

Yasuto Akiyama1, Akira Iizuka1, Akiko Kume1

  • 1Immunotherapy Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka, Japan.

Cancer Genomics & Proteomics
|May 16, 2015
PubMed
Abstract

Insights

STAT3 inhibition suppresses cancer growth by reversing the Warburg effect. This study identifies latexin as a tumor suppressor and ALDOA as a metabolic target for STAT3-targeting cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • Signal transducer and activator of transcription (STAT)3 promotes the Warburg effect, a metabolic shift crucial for cancer cell proliferation.
  • Developing effective STAT3 inhibitors requires identifying novel proteomic and metabolic targets.
  • Multi-omics approaches are essential for understanding STAT3 inhibition's impact on tumor growth.

Purpose of the Study:

  • To investigate the effects of STAT3 inhibition on metabolic switching in cancer cells.
  • To identify novel proteomic and metabolic markers for STAT3-targeting cancer therapy.
  • To explore the role of STAT3 in mediating the Warburg effect and tumor growth.

Main Methods:

  • Utilized short hairpin (sh)RNA to inhibit STAT3 in SCC-3 lymphoma cells.
  • Employed 2D differential gel electrophoresis and CE-TOF MS for proteomic and metabolic profiling.
  • Analyzed STAT3 inhibition effects on tumor growth in a mouse xenograft model.

Main Results:

  • STAT3 inhibition suppressed tumor growth in STAT3-activated SCC-3 cells.
  • Identified latexin as a potential proteomic marker and fructose-bisphosphate aldolase A (ALDOA) as a metabolic marker.
  • Observed latexin upregulation in multiple cancer cell lines and xenograft tumors following STAT3 inhibition.

Conclusions:

  • STAT3 inactivation reverses the glycolytic shift by downregulating key metabolic enzymes.
  • Latexin upregulation acts as a tumor-suppressor mechanism, contributing to apoptosis and growth inhibition.
  • These findings highlight latexin and ALDOA as potential therapeutic targets for STAT3-driven cancers.
Keywords:
STAT3Warburg effectcancer metabolomicsproteomicsshRNA

More Related Videos

SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry10:16

SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry

Published on: January 6, 2017

7.7K
Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

5.2K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K